Tuesday, June 3, 2025

Single-Cell #Analysis of Host Responses in #Bovine #Milk Somatic Cells (bMSCs) Following #HPAIV Bovine #H5N1 #Influenza Exposure

Abstract

The 2024 outbreak of highly pathogenic avian influenza virus (HPAIV) H5N1 in U.S. dairy cattle presented an unprecedented scenario where the virus infected bovine mammary glands and was detected in milk, raising serious concerns for public health and the dairy industry. Unlike previously described subclinical influenza A virus (IAV) infections in cattle, H5N1 infection induced severe clinical symptoms, including respiratory distress, mastitis, and abnormal milk production. To understand the host immune responses and changes, particularly in the mammary gland, we performed single-cell RNA sequencing analysis on bovine milk somatic cells (bMSCs) in vitro exposed to an H5N1 isolate from an infected dairy farm. We identified ten distinct cell clusters and observed a shift toward type-2 immune responses, characterized by T cells expressing IL13 and GATA3, and three different subtypes of epithelial cells based on the expression of genes associated with milk production. Our study revealed temporal dynamics in cytokine expression, with a rapid decline in luminal epithelial cells and an increase in macrophages and dendritic cells, suggesting a role in increased antigen presentation. While viral RNA was detected in bulk-exposed bMSC samples via qRT-PCR, no viral reads were observed in the scRNA-seq data, indicating that the immune responses captured may be due to exposure to viral components rather than productive infection. This research fills a critical gap in understanding the immune responses of bovine mammary glands to H5N1 exposure and highlights the need for further investigation into therapeutic strategies for managing such outbreaks.

Source: Viruses, https://www.mdpi.com/1999-4915/17/6/811

____

Monday, June 2, 2025

Recurrent #MERS-CoV #Transmission in #Saudi Arabia– Renewed Lessons in #Healthcare #Preparedness and Surveillance

{Excerpt}

The World Health Organization (WHO) had recently announced on May 12, 2025, the reporting of nine new laboratory-confirmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Saudi Arabia [1]. This announcement is a sobering reminder that while the global community remains focused on emergent threats like avian influenza or post-pandemic resilience, endemic zoonotic diseases like MERS-CoV may continue to circulate, evolve, and exploit gaps in infection prevention.

(...)

Source: Journal of Epidemiology and Global Health, https://link.springer.com/article/10.1007/s44197-025-00426-6

____

#Philippines - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification [FINAL]

The samples collected in two (2) wild bird species: Red Shank (Tringa totanus) and Arctic Warbler (Phylloscopus borealis), that tested positive for Notifiable Avian Influenza Subtype H5N1 were part of the regular wildlife disease surveillance activity being conducted by the wetland park. In response, additional samples were collected from wild birds, and all tested negative for Avian Influenza. Comprehensive surveillance and sample collection efforts in the surrounding domestic poultry population also confirmed no presence of Avian Influenza.

Source: WOAH, https://wahis.woah.org/#/in-review/6523

____

#Latvia - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

HPAI H5N1 confirmed in backyard poultry farm with approx. 190 birds (laying hens). Susupicion date 27/05/2025 - some birds with neurological signs, one dead. Laboratory diagnosis confirmed at the Latvian National Reference Laboratory for avian influenza.

Source: WOAH, https://wahis.woah.org/#/in-review/6528

____

Sunday, June 1, 2025

The Jabach Altarpiece, Albrecht Durer (1504)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/albrecht-durer/the-jabach-altarpiece-1504

____

Saturday, May 31, 2025

#Coronavirus Disease Research #References (by AMEDEO, May 31 '25)


 

    Am J Respir Crit Care Med

  1. KRISHNAN JA, Cao B, Chotirmall SH, Ely EW, et al
    Using the 2024 NASEM Definition of Long COVID: Implications for Pulmonary and Critical Care Medicine.
    Am J Respir Crit Care Med. 2025.
    PubMed        


    BMJ

  2. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
    Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
    BMJ. 2025;389:e081165.
    PubMed         Abstract available

  3. BOSAEED M, Alraddadi BM
    Navigating the complexities of mild and moderate covid-19 treatment.
    BMJ. 2025;389:r1016.
    PubMed        

  4. TANNE JH
    US no longer recommends covid-19 vaccinations for pregnant women or children.
    BMJ. 2025;389:r1104.
    PubMed        

  5. O'DOWD A, Iacobucci G
    Covid-19: Early call to test healthcare staff was ignored, inquiry hears.
    BMJ. 2025;389:r1092.
    PubMed        


    Clin Infect Dis

  6. WOLFE CR, Cohen J, Mahoney K, Holmes A, et al
    Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).
    Clin Infect Dis. 2025 May 24:ciaf265. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  7. ROSAS IO, Benitez A, McKinnell JA, Shah R, et al
    Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia.
    Emerg Infect Dis. 2025;31:1158-1168.
    PubMed         Abstract available


    Int J Infect Dis

  8. DEBIE Y, Verbruggen L, Peeters M, van Dam PA, et al
    mRNA COVID-19 vaccines induce superior IgA titers in cancer patients compared to viral vector vaccines: Implications for immunization strategies.
    Int J Infect Dis. 2025 May 23:107939. doi: 10.1016/j.ijid.2025.107939.
    PubMed         Abstract available


    J Infect

  9. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
    J Infect. 2025;91:106522.
    PubMed        


    J Med Virol

  10. PIAZZESE C, Williams S, Brentall A, Kele B, et al
    Analysis of Variants' Dynamic Using the CLIMB Database in COVID-19 Patients Admitted to Hospitals of Barts Health NHS Trust.
    J Med Virol. 2025;97:e70402.
    PubMed         Abstract available

  11. LIU K, Rao J, Hu X, Sun H, et al
    Maternal Vaccination and Protective Immunity Against SARS-CoV-2 Infection in Pups.
    J Med Virol. 2025;97:e70418.
    PubMed         Abstract available

  12. PENG W, Wei X, Wu Y, Shi C, et al
    Dynamic Molecular Changes in Brain, Lung, and Heart of Hamsters Infected With SARS-CoV-2: Insights From a Severe and Recovery Phase Model.
    J Med Virol. 2025;97:e70410.
    PubMed         Abstract available

  13. ALIYARI SR, Shanaa J, Yu D, Yamamoto M, et al
    Suppression of Monkeypox Virus by Downregulation of Fatty Acid Synthase and Upregulation of Cholesterol-25 Hydroxylase.
    J Med Virol. 2025;97:e70403.
    PubMed         Abstract available


    J Virol

  14. WANG Y, Tong W, Qin W, Yang X, et al
    Midnolin inhibits coronavirus proliferation by degrading viral proteins.
    J Virol. 2025 May 29:e0036625. doi: 10.1128/jvi.00366.
    PubMed         Abstract available

  15. GUO L, Duan X, Li J, Hao Z, et al
    YIPF5 is an essential host factor for porcine epidemic diarrhea virus double-membrane vesicle formation.
    J Virol. 2025 May 27:e0032025. doi: 10.1128/jvi.00320.
    PubMed         Abstract available

  16. POGANY J, Inaba J-i, Liu Y, Nagy PD, et al
    Screening bacterial effectors and human virus proteins in yeast to identify host factors driving tombusvirus RNA recombination: a role for autophagy and membrane phospholipid content.
    J Virol. 2025 May 27:e0166124. doi: 10.1128/jvi.01661.
    PubMed         Abstract available


    Lancet Infect Dis

  17. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.
    Lancet Infect Dis. 2025 May 21:S1473-3099(25)00153.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  18. LAMBROU AS, South E, Midgley CM, Harrington C, et al
    Update on the Epidemiology of Middle East Respiratory Syndrome Coronavirus - Worldwide, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2025;74:313-320.
    PubMed         Abstract available


    Nature

  19. HILL R, Yin Y, Stein C, Wang X, et al
    The pivot penalty in research.
    Nature. 2025 May 28. doi: 10.1038/s41586-025-09048.
    PubMed         Abstract available

  20. ZHAO Y, Zheng B, Saunois M, Ciais P, et al
    Air pollution modulates trends and variability of the global methane budget.
    Nature. 2025 May 28. doi: 10.1038/s41586-025-09004.
    PubMed         Abstract available


    Radiologia (Engl Ed)

  21. PEREZ LAENCINA M, Plasencia Martinez JM, Sanchez Canales M, Jimenez Pulido C, et al
    A commercial AI tool untrained for COVID-19 demonstrates slight improvement in the interpretation of COVID-19 pneumonia x-rays, especially among inexperienced readers.
    Radiologia (Engl Ed). 2025;67:273-286.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 31 '25)


 

    Arch Virol

  1. LIU X
    ACE2, a therapeutic target of COVID-19, needs to be treated with caution.
    Arch Virol. 2025;170:143.
    PubMed         Abstract available


    BMJ

  2. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
    Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
    BMJ. 2025;389:e081165.
    PubMed         Abstract available


    J Immunol

  3. DING C, Chen Q, Shi Y, Liu J, et al
    Impact of CD4+ T cell and TCR repertoires on SARS-CoV-2-Specific antibody responses in PLWH following COVID-19 vaccination.
    J Immunol. 2025 Apr 15:vkae040. doi: 10.1093.
    PubMed         Abstract available


    J Infect

  4. PETER RS, Sedelmaier L, Nieters A, Brockmann SO, et al
    Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study.
    J Infect. 2025;90:106500.
    PubMed         Abstract available

  5. HOOG M, Westrhenen ESH, Winkel AM, Jong MD, et al
    Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts.
    J Infect. 2025 May 9:106501. doi: 10.1016/j.jinf.2025.106501.
    PubMed         Abstract available

  6. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    PubMed         Abstract available

  7. OVERTON CE, Fyles M, Mellor J, Paton RS, et al
    SARS-CoV-2 test sensitivity and duration of positivity in the UK during the 2023/2024 Winter: A prospective cohort study based on self-reported data.
    J Infect. 2025;90:106485.
    PubMed         Abstract available

  8. CHEN R, Hao Z, Ye J, Zhao X, et al
    Decoding Post-Mortem Infection Dynamics of SARS-CoV-2, IAV and RSV: New Insights for Public Health and Emerging Infectious Diseases Management.
    J Infect. 2025 Apr 21:106489. doi: 10.1016/j.jinf.2025.106489.
    PubMed         Abstract available


    J Virol

  9. ZHANG Q, Zhang L, Li J, Zhang W, et al
    hnRNPM regulates influenza A virus replication through distinct mechanisms in human and avian cells: implications for cross-species transmission.
    J Virol. 2025 May 28:e0006725. doi: 10.1128/jvi.00067.
    PubMed         Abstract available


    JAMA

  10. MOIN EE, Seewald NJ, Halpern SD
    Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
    JAMA. 2025 Apr 14:e252163. doi: 10.1001/jama.2025.2163.
    PubMed         Abstract available


    PLoS Comput Biol

  11. ZHANG R, Tai J, Yao Q, Yang W, et al
    Behavior-driven forecasts of neighborhood-level COVID-19 spread in New York City.
    PLoS Comput Biol. 2025;21:e1012979.
    PubMed         Abstract available

  12. MEDINA CM, Palacios JA, Minin VM
    Accounting for reporting delays in real-time phylodynamic analyses with preferential sampling.
    PLoS Comput Biol. 2025;21:e1012970.
    PubMed         Abstract available


    PLoS One

  13. REHMAN N, Mbuagbaw L, Mertz D, Muraca GM, et al
    Association between virtual visits and health outcomes of people living with HIV: A cross-sectional study.
    PLoS One. 2025;20:e0315880.
    PubMed         Abstract available

  14. DHAR B, Sajid M
    On improving public health after COVID-19 epidemic: A fractal-fractional mathematical solutions with short memory effect and efficient optimal strategies.
    PLoS One. 2025;20:e0321195.
    PubMed         Abstract available

  15. KUANG D, Gao X, Du N, Huang J, et al
    Wastewater surveillance as a predictive tool for COVID-19: A case study in Chengdu.
    PLoS One. 2025;20:e0324521.
    PubMed         Abstract available

  16. HONDA R, Abe T, Baba T, Araki Y, et al
    Dissemination of local sub-variants of SARS-CoV-2 detected by detailed mutation analysis in wastewater-based epidemiology.
    PLoS One. 2025;20:e0317076.
    PubMed         Abstract available

  17. HAN Z, Chen M, Wang Y
    The impact of COVID-19 stress on nurses' organizational deviance: A moderated mediation model.
    PLoS One. 2025;20:e0324992.
    PubMed         Abstract available

  18. CAZER CL, Lawless JW, Mehta P, Wagner B, et al
    Prevalence of SARS-CoV-2 infection and immunity in a New York county in 2022 reveals frequent asymptomatic or undiagnosed infections.
    PLoS One. 2025;20:e0323659.
    PubMed         Abstract available

  19. AXEN I, Weiss N, Skillgate E
    Manual therapists in Sweden during the COVID-19 pandemic -they remained in business, but how was their work environment and practice impacted?
    PLoS One. 2025;20:e0324245.
    PubMed         Abstract available

  20. HEYDARI P, Meyer MN, Chabris CF
    Medical rationing choices of laypeople and clinicians are often illogical and inconsistent with their own stated preferences.
    PLoS One. 2025;20:e0322242.
    PubMed         Abstract available

  21. ALTARE C, Kim K, Spiegel PB
    "Everything had stopped, no meeting, no gathering": Social interactions during the COVID-19 pandemic in the Central African Republic, the Democratic Republic of Congo, and Bangladesh.
    PLoS One. 2025;20:e0323108.
    PubMed         Abstract available

  22. KENGNE KAMGA LS, Voordouw ACG, De Vries MC, Kemper S, et al
    The citizen's perception of a shared responsibility during the COVID-19 management: Insights from a focus group study across four European countries.
    PLoS One. 2025;20:e0322019.
    PubMed         Abstract available

  23. RUSSO FF
    Testing policies during an epidemic: An economic analysis.
    PLoS One. 2025;20:e0322292.
    PubMed         Abstract available

  24. POORBAUGH J, Sims JT, Zhang L, Chang CY, et al
    Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.
    PLoS One. 2025;20:e0324242.
    PubMed         Abstract available

  25. MANUEL DG, Bennett C, Brown E, Buckeridge DL, et al
    Developing an evaluation framework for public health environmental surveillance: Protocol for an international, multidisciplinary Delphi consensus study.
    PLoS One. 2025;20:e0310342.
    PubMed         Abstract available

  26. SHIMIZU HE, Gomes AMT, Apostolidis T
    The social representations of Covid-19 among primary health care' users in the Federal district, Brazil: A psychosocial approach.
    PLoS One. 2025;20:e0323568.
    PubMed         Abstract available

  27. MA X, Huang T, Song Y, Pan H, et al
    Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.
    PLoS One. 2025;20:e0323708.
    PubMed         Abstract available

  28. NYONGESA V, Kathono J, Mwavua S, Nyamai D, et al
    "If I tell you my problems, how will you perceive me?": A qualitative study of mental health knowledge, barriers, and opportunities for care among Kenyan adolescents during COVID-19.
    PLoS One. 2025;20:e0323907.
    PubMed         Abstract available

  29. SONG MC, Ha J, Park S, Kang H, et al
    Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.
    PLoS One. 2025;20:e0323736.
    PubMed         Abstract available

  30. NATALIA YA, Molenberghs G, Neyens T, Hens N, et al
    Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021.
    PLoS One. 2025;20:e0322017.
    PubMed         Abstract available

  31. KULJANCIC D, Amidzic J, Ljubotin L, Siladji D, et al
    Clinical profile of alcohol dependent paintents according to Lesch Typology one year after the Covid-19 pandemic-comparative study.
    PLoS One. 2025;20:e0324851.
    PubMed         Abstract available


  32. Retraction: Comprehensive computational analysis reveals H5N1 influenza virus-encoded miRNAs and host-specific targets associated with antiviral immune responses and protein binding.
    PLoS One. 2025;20:e0325170.
    PubMed        

  33. COLMAN E, Kao R
    The impact of signal variability on COVID-19 epidemic growth rate estimation from wastewater surveillance data.
    PLoS One. 2025;20:e0322057.
    PubMed         Abstract available

  34. WANG CN, Nguyen TTM, Nhieu NL, Chung YC, et al
    Performance evaluation of Vietnamese industrial goods and services during and post-COVID-19 era based on multi-criteria decision-making methods.
    PLoS One. 2025;20:e0323764.
    PubMed         Abstract available

  35. VAN DER MOEREN N, van den Biggelaar R, Gast KB, Verweij JJ, et al
    The added diagnostic value of RT-PCR on faeces for the diagnosis of COVID-19.
    PLoS One. 2025;20:e0322543.
    PubMed         Abstract available

  36. BENTAHAR I, Loubet P, Salipante F, Choquet C, et al
    Respiratory viruses Ct values and association with clinical outcomes among adults visiting the ED with lower respiratory tract infections.
    PLoS One. 2025;20:e0320503.
    PubMed         Abstract available


    Vaccine

  37. RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
    Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
    Vaccine. 2025;59:127293.
    PubMed         Abstract available

  38. QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
    Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
    Vaccine. 2025;58:127223.
    PubMed         Abstract available

  39. LUPTON D, Whitten T, Tay AK, Beek K, et al
    Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
    Vaccine. 2025;58:127251.
    PubMed         Abstract available

  40. AVERIN A, Quinn E, Atwood M, Weycker D, et al
    Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
    Vaccine. 2025;58:127191.
    PubMed         Abstract available

  41. SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
    Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
    Vaccine. 2025;58:127267.
    PubMed         Abstract available

  42. MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
    Childhood vaccine hesitancy: The power of metaphors.
    Vaccine. 2025;58:127221.
    PubMed         Abstract available

  43. PATTYN J, Hanning N, Valckx S, Claessens T, et al
    Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
    Vaccine. 2025;58:127250.
    PubMed         Abstract available

  44. MERRITT A, Bansal S
    Prison Vaccination in a pandemic: Geographic disparities and policy insights.
    Vaccine. 2025;58:127218.
    PubMed         Abstract available

  45. PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
    Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
    Vaccine. 2025;57:127222.
    PubMed         Abstract available

  46. WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
    Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
    Vaccine. 2025;58:127179.
    PubMed         Abstract available

  47. STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
    Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
    Vaccine. 2025;57:127232.
    PubMed         Abstract available

  48. ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
    Reactance as a cause of COVID-19 vaccination hesitancy.
    Vaccine. 2025;57:127209.
    PubMed         Abstract available

  49. ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
    New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
    Vaccine. 2025;57:127217.
    PubMed         Abstract available

  50. MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
    Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
    Vaccine. 2025;59:127297.
    PubMed         Abstract available

  51. SEILER P, Kaplan BS, Brice DC, Duan S, et al
    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
    Vaccine. 2025;60:127311.
    PubMed         Abstract available


    Virology

  52. LENDE SSF, Rothemejer FH, Andreas M, Pedersen ML, et al
    Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis.
    Virology. 2025;610:110573.
    PubMed         Abstract available

History of Mass Transportation: The FS D461 Diesel-Electric Locomotive

 


By Domenvadrouille - Flickr: les pieces de collections, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=17692704

Source: WikiPedia, https://it.wikipedia.org/wiki/Locomotiva_FS_D.461

____

#Brazil’s First #H5N1 #Outbreak in Commercial #Poultry: A #Sentinel Event for Cross-Border #Preparedness

Highlight

Brazil’s first confirmed H5N1 outbreak in commercial poultry marks a critical shift in South America’s avian influenza landscape. The event calls for strengthened coordination between animal and human health sectors, improved border surveillance, and early-warning systems to reduce zoonotic risk in regions with growing poultry production and international connectivity.

Source: Journal of Travel Medicine, https://academic.oup.com/jtm/advance-article-abstract/doi/10.1093/jtm/taaf050/8153894?redirectedFrom=fulltext

____

Friday, May 30, 2025

#Evidence of #Viremia in Dairy #Cows Naturally Infected with #Influenza A {#H5N1} Virus, #California, #USA

Abstract

We confirmed influenza A virus (IAV) by PCR in serum from 18 cows on 3 affected dairy farms in California, USA. Our findings indicate the presence of viremia and might help explain IAV transmission dynamics and shedding patterns in cows. An understanding of those dynamics could enable development of IAV mitigation strategies.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/7/25-0134_article

____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater (US CDC, May 29 '25) {Updated}

 


{Excerpt}

Time Period: May 18, 2025 - May 24, 2025

-- H5 Detection17 sites (5.0%)

- No Detection322 sites (95.0%)

- No samples in last week116 sites






(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html

____

#Surveillance and #Coinfection Dynamics of Infectious Bronchitis Virus and Avian #Influenza #H9N2 in Moroccan Broiler Farms (2021–2023): Phylogenetic Insights and Impact on Poultry Health

Abstract

Infectious bronchitis virus (IBV) and low-pathogenic avian influenza virus (LPAIV) H9N2 are commonly identified in poultry, individually or in association with other pathogens. This study monitored 183 broiler farms affected by respiratory diseases across seven regions of Morocco from January 2021 to December 2023. Among these farms, 87.98% were vaccinated against IBV, while 57.92% were against AI H9N2. Abnormally high mortality rates were observed in 44.26% of the farms, with 24.69% of cases attributed to IBV, 50.62% to LPAI H9N2, and 13.58% due to coinfection with both IBV and H9N2. RT-PCR analysis of tissue samples and cloacal and tracheal swabs collected from 183 broiler farms revealed that 33.33% were positive for IBV and 34.97% for H9N2. Coinfection by IBV and H9N2 was detected in 12.57% of cases, peaking at 17% in 2022. Co-infected flocks exhibited severe clinical signs and lesions, such as reduced food consumption, diarrhea, and renal issues. The predominant lesions were in the respiratory tract, affecting 91.26% of infected broilers. Additionally, among the 183 flocks, 50 farms that tested positive for IBV infection were randomly selected from the seven regions of Morocco for further investigation of other respiratory pathogens, including Mycoplasma gallisepticum (MG), Mycoplasma synoviae (MS), and infectious laryngotracheitis (ILT), using real-time RT-PCR. Detection rates for these pathogens were 26% for MG, 30% for MS, 4% for ILTv (vaccine strain), and 18% for ILTw (wild strain). Detection rates for single, dual, triple, and quadruple infections were 34%, 42%, 18%, and 4%, respectively. The most common dual and triple coinfections were IBV + H9N2 (14%) and IBV + MG + MS (10%). Phylogenetic analysis of the S gene identified two main IBV genotypes, namely, 793B and D181, with the latter being a strain circulating for the first time in Moroccan poultry. This underscores the urgent need to establish surveillance systems to track pathogen circulation and implement strategies to control virus spread, ensuring the protection of animals and public health.

Source: Viruses, https://www.mdpi.com/1999-4915/17/6/786

____

Thursday, May 29, 2025

#Anthrax - #Thailand (#WHO, D.O.N., May 29 '25)

 


{Summary}

Situation at a glance

In early May 2025, the International Health Regulations National Focal Point (IHR NFP) for Thailand notified WHO of four cases of cutaneous anthrax

One of the affected individuals died as a result of disease complications, while the remaining three cases were hospitalized and received appropriate medical care

All reported cases had direct contact with cattle suspected to be infected with anthrax. 

A rapid field investigation and response was conducted by the national health authorities. 

All potentially exposed individuals were identified, and all high-risk contacts received post-exposure prophylaxis

On 28 May, an additional case was announced who was associated with the slaughtering of cattle

Disease control measures, including animal quarantine, and vaccination campaign targeting cattle withing five km radius, public awareness campaigns, and enhanced surveillance, were implemented in the affected area. 

Anthrax is a life-threatening zoonotic disease caused by the spore-forming bacterium Bacillus anthracis

Humans can get anthrax from infected animals or contaminated animal products. 

It generally does not spread between people. 

Currently, due to the robust public health measures implemented by Thailand, the risk of international disease spread through animal movement remains low.

(...)

Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573

____

#Update on the #Epidemiology of Middle East Respiratory Syndrome {#MERS} #Coronavirus — #Worldwide, 2017–2023 (US CDC, MMWR)

 


Summary

-- What is already known about this topic?

- Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is a zoonotic virus transmitted sporadically from camels to humans, with limited subsequent human-to-human transmission. Most reported human cases of MERS have occurred in or near the Arabian Peninsula. Standardized clinical and epidemiologic criteria are used to determine who in the United States should be tested for MERS-CoV. In the United States, the last identified and confirmed MERS cases occurred in 2014.

-- What is added by this report?

- Global reported MERS cases have declined substantially since the COVID-19 pandemic. Numbers of travelers entering the United States from in or near the Arabian Peninsula declined during the COVID-19 pandemic, but now have returned to prepandemic levels. U.S. MERS-CoV testing declined during 2017–2023 and remains low relative to prepandemic years. Clinical and epidemiologic criteria to guide U.S. testing were updated in 2024.

-- What are the implications for public health practice?

- Though global reported MERS cases have declined substantially, continued MERS-CoV surveillance is important to maintaining MERS preparedness and response capabilities.


Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus transmitted sporadically from camels to humans. Most reported human Middle East respiratory syndrome (MERS) cases have occurred in or near the Arabian Peninsula. Limited human-to-human transmission can occur after close contact and has resulted in health care–associated outbreaks. Global reported MERS cases, U.S. testing data, and data on incoming U.S. travelers originating in and near the Arabian Peninsula during 2017–2023 were analyzed to guide U.S. MERS preparedness. Global MERS cases reported to the World Health Organization declined during the COVID-19 pandemic and remain substantially lower than during years preceding the pandemic. U.S. MERS-CoV testing numbers also declined and remain low relative to the prepandemic period. Although the number of travelers coming to the United States from in or near the Arabian Peninsula declined during the pandemic, incoming traveler volume returned to prepandemic levels. Further investigations are needed to determine whether the decline in global MERS cases reflects a true decrease in the number of infections, underascertainment of cases, or a combination. U.S. MERS persons under investigation criteria, standard clinical and epidemiologic characteristics used to guide who in the U.S. is tested for MERS-CoV, were updated in 2024 and can be used to guide clinicians and jurisdictional public health partners when considering MERS-CoV testing. Continued and targeted MERS-CoV material surveillance is important to maintaining preparedness and promptly responding to potential MERS cases.

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/mmwr/volumes/74/wr/mm7419a1.htm?s_cid=mm7419a1_e&ACSTrackingID=USCDC_921-DM147411&ACSTrackingLabel=This%20Week%20in%20MMWR%3A%20Vol.%2074%2C%20May%2029%2C%202025&deliveryName=USCDC_921-DM147411

____

Altered germinal center responses in mice vaccinated with highly pathogenic avian #influenza A(#H5N1) virus

Highlights

• Different immune responses in mice vaccinated with influenza A(H5N1) than with other subtypes.

• Highly pathogenic avian influenza A(H5N1)-vaccinated mice had altered germinal center responses.

• A(H5N1)-vaccinated mice had fewer dLN germinal centers and more extrafollicular B cells.

• A(H5N1)-vaccinated mice had more dLN follicular helper and regulatory T cells.

• Our study represents a timely assessment of A(H5N1) risk to human health.


Abstract

Highly pathogenic avian influenza (HPAI) H5N1 virus vaccines typically yield lower neutralizing antibody titers in animals than influenza A virus (IAV) vaccines derived from other viral subtypes. To understand these differences, we compared the cellular immune responses in the draining lymph nodes (dLNs) of mice vaccinated with an inactivated whole H5N1 vaccine to those in mice vaccinated with seasonal H1N1pdm09, H7N9, or H9N2 IAV vaccines. H5N1-vaccinated mice exhibited reduced serum neutralizing antibody titers, despite the hemagglutinin-binding immunoglobulin production being similar to that with other IAV vaccines. Although bulk RNA sequencing showed no differences in B-cell populations after H5N1 and H1N1pdm09 vaccination, H5N1 vaccination resulted in fewer, but larger, dLN germinal centers and significantly more extrafollicular B cells, which are known to produce lower neutralizing antibody titers. Furthermore, H5N1-vaccinated mice had significantly more follicular helper and regulatory T cells. Therefore, differences in neutralizing antibody production in mice after IAV vaccination correlate with subtype-dependent germinal center reactions in the dLNs.

Source: Vaccine, https://www.sciencedirect.com/science/article/pii/S0264410X25006085?via%3Dihub

____

Stability of #influenza viruses in the #milk of #cows and #sheep

Abstract

In late 2023, H5N1 high pathogenicity avian influenza (HPAIV) started circulating in dairy cattle in the USA. High viral titres were detected in milk from infected cows, raising concerns about onwards human infections. Although pasteurisation was shown to effectively inactivate influenza viruses in milk, unpasteurised milk still poses a risk of infection, both from occupational exposure in dairies and from the consumption of raw milk. We therefore assessed how long influenza viruses could remain infectious for in milk without heat inactivation. We examined the stability of a panel of influenza viruses in milk, including a contemporary H5N1 HPAIV and a variety of other influenza A and D viruses. We incubated viruses in cows' milk under laboratory conditions: at room temperature to simulate exposure in dairies and at 4°C to simulate exposure to refrigerated raw milk. Following an isolated report of H5N1 viral RNA being detected in milk from a sheep in the UK, we also carried out similar experiments with a laboratory strain of IAV in sheep's milk. Although the survival of influenza viruses in milk was variable, we consistently found that under laboratory conditions substantial viral infectivity remained over periods when people might reasonably be exposed to infected milk - for over a day at room temperature and for more than 7 days when refrigerated. Our results highlight the zoonotic risk of H5N1 HPAIV in raw milk from infected animals and reinforce the importance of taking measures to mitigate this risk.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.05.28.25328508v1

____

G57 #genotype of BJ/94-like #H9N2 lineage exhibits increased #replication & virulence in chickens compared to G1 Middle East Group B lineage

Abstract

Avian influenza H9N2 viruses cause significant economic losses to the poultry industry and pose a public health risk due to their potential to reassort with other avian influenza viruses, generating strains with zoonotic and pandemic potential. Two major H9N2 lineages dominate globally: the G1 lineage (genotype G1-B), prevalent in the Middle East, Africa and the Indian subcontinent, and the BJ/94 lineage (predominantly genotype G57), dominant in China, Vietnam, South Korea, Indonesia, and the Far East. We investigated replication, transmission, and pathogenicity of representatives of these two lineages, linking genotype to phenotype. The G57 strain A/Ck/Vietnam/H7F-14-BN4-315/2014 (Vietnam/315) was more lethal to chicken embryos than the G1-B strain A/chicken/Pakistan/UDL-01/2008 (Pakistan/UDL-01). Vietnam/315 exhibited higher replication in both directly infected and contact chickens, with increased virus shedding from the oropharynx and cloaca. In contrast, Pakistan/UDL-01 virus was primarily shed from the oropharynx, highlighting differences in replication, tissue tropism and transmission. Gene analysis showed the M gene of Vietnam/315 enhanced replication in primary chicken kidney cells, whereas the PB2, HA, NA, and M genes promoted increased replication in Madin-Darby Canine Kidney cells. Both viruses showed preferential binding to avian-like receptors over human-like receptors. However, Vietnam/315, however, exhibited higher neuraminidase activity and a more acid-stable HA (pH fusion 5.2) than Pakistan/UDL-01 virus. These findings suggest G57 genotype viruses possess greater replication and transmission fitness than G1-B viruses in vivo, ex vivo and in vitro. Reassortment events involving G1-B strains acquiring G57 genes may enhance replication and virulence, potentially increasing the risk of animal and human infection.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.05.28.656345v1

____

Wednesday, May 28, 2025

Post-mortem #investigation of role of endemic #human #coronaviruses in causal pathway to death amongst #children under 5 in LMIC: findings from the Child Health & Mortality Prevention Surveillance

Highlights

• Large study on the contribution of HCoV to childhood deaths

• Supports vigilance or further investigations into HCoV pathogenesis

• Potential information for the role Covid-19 will play during severe childhood disease

• Highlights the importance of polymicrobial infection during severe disease episodes


Abstract

Background

Endemic human coronaviruses (HCoV-229E, HKU1, NL63, and OC43) are common causes of mild or asymptomatic respiratory infections in children but are considered rare causes of death.

Methods

We evaluated paediatric deaths from January 2017 through December 2022. A panel of experts determined the cause of death (CoD) by reviewing available data, including pathological and molecular findings from minimally invasive tissue sampling (lung tissues, blood, CSF, and nasopharyngeal swabs), clinical records, and verbal autopsies.

Results

Endemic HCoV were detected in the respiratory samples of 3% (n=86/3357) of enrolled decedents: 1% (n=12/2043) of neonates, 5%(n=35/681) of infants and 6% (n=39/633) of children deaths. However, HCoVs were attributed as the CoD in only two cases — both involving young infants with underlying birth defects and severe wasting, who succumbed to polymicrobial hospital-acquired infections involving HCoV-OC43, Klebsiella pneumoniae, and Acinetobacter baumannii. Amongst the remaining 84 decedents in whom an HCoV was detected, 82% (n=69/84; median Ct of 25.34; range:15.28-36.17) were deaths attributed to other infections, including 54% (n=32/69; median Ct of 23.86; range:15.28-35.2) with lower respiratory infections determined to be the CoD. The bulk of these deaths (96%,n=66/69) were attributed to other pathogens - Plasmodium falciparum (27%,n=19/69), K.pneumoniae (23%,n=16/69), Streptococcus pneumoniae (20%,n=14/69), Escherichia coli (16%,n=11/69) and Cytomegalovirus (10%,n=7/69).

Conclusion

Although endemic HCoV was identified in children who died of respiratory infections, it was rarely attributed to being in the CoD. Nevertheless, further research is warranted to explore the potential role of HCoVs in LRTI pathogenesis and their impact on facilitating more pathogenic infections.

Source: Journal of Clinical Virology, https://www.sciencedirect.com/science/article/abs/pii/S1386653225000460?dgcid=rss_sd_all

____

hnRNPM regulates #influenza A virus #replication through distinct mechanisms in #human and #avian cells: implications for cross-species transmission

ABSTRACT

The eight-segmented RNA genome of influenza A virus (IAV) is transcribed and spliced into 10 major viral mRNAs in the nucleus of infected cells. Both transcription and splicing are facilitated by the host RNA polymerase II (Pol II) machinery via interactions between the viral ribonucleoprotein (vRNP) complex and various host factors. In this study, we demonstrate that IAV vRNPs recruit species-specific heterogeneous nuclear ribonucleoprotein M (hnRNPM) to support their replication in human and avian cells through distinct mechanisms. In A549 cells, human hnRNPM specifically facilitates the efficient transcription of HA, NA, M, and NS segments of WSN virus in a gene coding sequence-dependent manner. In contrast, in DF-1 cells, chicken hnRNPM restricts excessive splicing of M segment mRNA to ensure proper M2 protein production. Notably, human hnRNPM, with 34 additional amino acids compared with its chicken counterpart, fails to inhibit the M2 expression in DF-1 cells, whereas both human and chicken hnRNPM regulate WSN virus replication similarly in A549 cells. These findings highlight the host-specific roles of M2 levels in IAV replication and reveal how IAV co-opts host factors through virus genome sequence-dependent and host species-specific mechanisms, underscoring its high flexibility and adaptability during cross-species transmission.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00067-25?af=R

____

Genomic and #Clinical #Analysis of a #Fatal Human #Lyssavirus irkut Case: Evidence for a Natural Focus in the Russian Far East

Abstract

In this report, we document and analyze a case in which the Irkut virus (IRKV) (Mononegavirales: Rhabdoviridae) caused a fatal human case following a bat bite in June 2021. Unfortunately, the available data did not permit a detailed taxonomic classification of the carrier bat (Chiroptera). The event occurred in the southwestern part of the Sikhote-Alin mountain region (Russian Far East) covered by the Ussuri taiga forest. The symptoms of the illness began with the following: fever; pronounced psychomotor and motor agitation; tremor of the lower jaw and tongue; aphasia; dyslexia; and dysphagia. These rapidly developed, leading to a severe and fatal encephalitis. The patient was not vaccinated for rabies and did not receive rabies immunoglobulin. Using brain sections prepared from the deceased, molecular diagnostics were performed: immunofluorescence (polyclonal anti-rabies immunoglobulin) indicating the presence of the lyssavirus antigen; and RT-PCR indicating traces of viral RNA. Sectional material (brain) was used for whole-genome sequencing, resulting in a near-complete sequence of the lyssavirus genome. The obtained genomic sequence was identified as the Irkut virus. A comparative analysis of the new sequence and other currently available IRKV sequences (NCBI) revealed differences. Specifically, amino acid differences between antigenic sites in the isolate and those of the rabies vaccine strain used regionally were noted. The patient history and subsequent analysis confirm human IRKV infection following bat contact. Like other fatal cases of IRKV infection described earlier, this case occurred in the southern part of the Russian Far East. Two have occurred in the southwestern part of the Sikhote-Alin mountain region. This indicates the possible existence of an active, natural viral focus.

Source: Viruses, https://www.mdpi.com/1999-4915/17/6/769

____

My New Space

Most Popular Posts